about the author

ENDPOINTS

editor@endpointsnews.com

author articles

#JPM24 quick hits: Io­n­is on part­ner­ship’s pros and cons; No­vo Ven­tures has $600M to spend; Are small mol­e­cules ...

Last year
R&D

#JPM24 quick hits: Vibe check; Maze’s next turn; AI at phar­ma com­pa­nies + more

Last year
Deals
AI

#JPM24 quick hits: A 'great year for M&A'; an op­ti­mistic Sarep­ta; Pfiz­er's CEO + more

Last year
Deals
R&D

Rhythm li­cens­es obe­si­ty drug for $100M; Gala­pa­gos teams up with Brid­Gene; In­sil­i­co’s new deal

Last year
News Briefing

All the new drugs ap­proved in 2023: Alzheimer's and gene ther­a­py cap a five-year high

Last year
FDA+

J&J’s new part­ner­ship with Elek­trofi; Enyo rais­es €39M; Ar­row­head­'s $450M of­fer­ing

Last year
News Briefing

The­seus goes with Tang; Onc­ter­nal tri­al pa­tient dies; Lian­Bio sells drug rights to J&J

Last year
News Briefing

The 2023 win­ners and losers list: Who was up and who was down in bio­phar­ma

Last year
Pharma

Rock­et’s gene ther­a­py gets a PDU­FA date; SAB Bio­ther­a­peu­tics’ $130M; Acurx to move to PhI­II

Last year
News Briefing

An­tios re­port­ed­ly shut down; Clene's long-term ALS da­ta; Keytru­da, Lenvi­ma's lung can­cer fail­ures

Last year
News Briefing

The End­points 11: The biotech star­tups mak­ing the biggest bets with the most ex­cit­ing sci­ence in 2023

Last year
Startups
Special

Ex­clu­sive: Af­ter Cure­Vac, Ig­or Splaws­ki moves to RTW stealth start­up; Lyn­dra's Jes­si­ca Ballinger adds CEO ti­tle amid ...

Last year
Peer Review

Spe­cial re­port 2023: Meet 20 women re­shap­ing bio­phar­ma

Last year
Special

The 20(+2) un­der 40: Your guide to the next gen­er­a­tion of biotech lead­ers

Last year
Special

Every drug ap­proved in 2022: A year of few­er new prod­ucts, but gene ther­a­py firsts and new block­busters

3 years ago
R&D
Special

News wrap: Equi­l­li­um ax­es Metacrine merg­er; Two phar­mas pen ADC deals

3 years ago
News Briefing

Spe­cial re­port 2022: Meet 20 women blaz­ing trails in bio­phar­ma R&D

3 years ago
Special

Ex-Take­da ex­ec hits the ground run­ning at the helm of rare dis­ease biotech — with 3 pri­or­i­ties off the bat; ...

3 years ago
Peer Review

The 20(+1) un­der 40: Your guide to the next gen­er­a­tion of biotech lead­ers

4 years ago
Special

BeiGene/No­var­tis tout new PD-1 da­ta; No­var­tis plans down­siz­ing in Tokyo

4 years ago
News Briefing

En­do reach­es opi­oid set­tle­ment in Flori­da; De­moc­rats call on CMS to low­er pre­mi­ums fol­low­ing Aduhelm price cut

4 years ago
News Briefing

Se­lec­ta turns to syn­bio play­er for $1.1B cap­sid deal; BioN­Tech signs $790M im­munother­a­py deal

4 years ago
News Briefing

2021's NDA list in­cludes some ex­tra­or­di­nary ac­com­plish­ments in year #2 of the pan­dem­ic

4 years ago
Special

End­points ed­i­tors se­lect the top trends of 2022: M&A looks hot as IPOs wane, it's time to see some hard da­ta on AI ...

4 years ago
Editor's note
Special
First page Previous page 9101112131415 Next page Last page
A service from the Financial Times